Other OTC - Delayed Quote USD

Innovent Biologics, Inc. (IVBXF)

5.0000 +0.1100 (+2.25%)
At close: April 26 at 3:06 PM EDT
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
5,018,313.0000
4,556,380.0000
4,269,729.0000
3,843,819.0000
Cost of Revenue
964,077.0000
930,990.0000
505,337.0000
387,761.0000
Gross Profit
4,054,236.0000
3,625,390.0000
3,764,392.0000
3,456,058.0000
Operating Expense
5,865,747.0000
6,207,275.0000
5,703,539.0000
3,498,501.0000
Operating Income
-1,811,511.0000
-2,581,885.0000
-1,939,147.0000
-42,443.0000
Net Non Operating Interest Income Expense
82,113.0000
87,839.0000
89,291.0000
47,752.0000
Pretax Income
-1,427,666.0000
-2,170,469.0000
-2,641,717.0000
-858,713.0000
Tax Provision
-59,715.0000
8,801.0000
87,038.0000
139,708.0000
Net Income Common Stockholders
-1,367,951.0000
-2,179,270.0000
-2,728,755.0000
-998,421.0000
Diluted NI Available to Com Stockholders
-1,367,951.0000
-2,179,270.0000
-2,728,755.0000
-998,421.0000
Basic EPS
-0.90
-1.46
-1.88
-0.74
Diluted EPS
-0.90
-1.46
-1.88
-0.74
Basic Average Shares
1,525,268.6820
1,490,123.1920
1,455,605.7510
1,357,011.7570
Diluted Average Shares
1,525,268.6820
1,490,123.1920
1,455,605.7510
1,357,011.7570
Total Expenses
6,829,824.0000
7,138,265.0000
6,208,876.0000
3,886,262.0000
Net Income from Continuing & Discontinued Operation
-1,367,951.0000
-2,179,270.0000
-2,728,755.0000
-998,421.0000
Normalized Income
-1,380,855.6738
-2,183,141.5000
-2,821,986.0000
-1,020,753.0000
Interest Income
102,700.0000
189,537.0000
151,755.0000
116,102.0000
Interest Expense
107,424.0000
101,698.0000
62,464.0000
68,350.0000
Net Interest Income
82,113.0000
87,839.0000
89,291.0000
47,752.0000
EBIT
-1,320,242.0000
-2,068,771.0000
-2,579,253.0000
-790,363.0000
EBITDA
-938,129.0000
-1,749,349.0000
-2,374,506.0000
-704,736.0000
Reconciled Cost of Revenue
964,077.0000
930,990.0000
505,337.0000
387,761.0000
Reconciled Depreciation
382,113.0000
319,422.0000
204,747.0000
85,627.0000
Net Income from Continuing Operation Net Minority Interest
-1,367,951.0000
-2,179,270.0000
-2,728,755.0000
-998,421.0000
Total Unusual Items Excluding Goodwill
13,468.0000
5,162.0000
124,308.0000
29,776.0000
Total Unusual Items
13,468.0000
5,162.0000
124,308.0000
29,776.0000
Normalized EBITDA
-951,597.0000
-1,754,511.0000
-2,498,814.0000
-734,512.0000
Tax Rate for Calcs
0.0000
0.0003
0.0003
0.0003
Tax Effect of Unusual Items
563.3262
1,290.5000
31,077.0000
7,444.0000
12/31/2020 - 9/4/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SIGY Sigyn Therapeutics, Inc.
6.34
+10.26%
 
BRCTF BioArctic AB (publ)
17.75
0.00%
 
NBIO Nascent Biotech, Inc.
0.0999
0.00%
 
IMUC EOM Pharmaceuticals Holdings, Inc.
0.1979
0.00%
 
ATBPF Antibe Therapeutics Inc.
0.2156
0.00%
 
WXIBF WuXi Biologics (Cayman) Inc.
1.6800
+2.13%
 
CDT Conduit Pharmaceuticals Inc.
3.1700
+0.32%
 
INBX Inhibrx, Inc.
34.06
-0.09%
 
OBIO Orchestra BioMed Holdings, Inc.
4.3900
-1.13%
 
9688.HK Zai Lab Limited
12.620
-0.16%